

Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/MC2B60DD57D8EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: MC2B60DD57D8EN

Abstracts

The 7 major metastatic prostate cancer markets are expected to exhibit a CAGR of 6.22% during 2024-2034.

The metastatic prostate cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic prostate cancer, also known as advanced or stage IV prostate cancer, is a form of neoplasm that originates in the prostate gland and spreads to other parts of the body. This condition occurs when cancerous cells break away from the primary tumor in the prostate and travel through the bloodstream or lymphatic system to different organs or tissues, where they form secondary tumors. Some common sites of metastasis associated with the disease include the bones, lymph nodes, liver, lungs, and other distant organs.

Individuals suffering from this ailment may experience increased frequency of urination, bone pain, a general sense of tiredness or weakness, loss of appetite, swelling, erectile dysfunction, weakness, numbness, problems with coordination, etc. The diagnosis of metastatic prostate cancer typically involves a review of the patient's clinical features, medical history, and a physical test, including a digital rectal exam. Various diagnostic studies, like positron emission tomography scans, bone scans, magnetic resonance imaging, etc., are also utilized to evaluate the extent of cancer and detect metastasis.

The increasing cases of genetic mutations that impair the cell's ability to repair DNA damage, which can result in the accumulation of additional variations and genomic instability, are primarily driving the metastatic prostate cancer market. Besides this, the rising incidences of hormonal imbalances, including elevated testosterone levels that can lead to overactivation of the androgen receptor, causing the tumor to grow

abnormally, are creating a positive outlook for the market. Moreover, the widespread adoption of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to stimulate the body's defense mechanism against cancerous cells is further bolstering the market growth. Apart from this, the escalating application of androgen deprivation therapy, since it aims to suppress the production or block the action of male hormones that enhance the proliferation of tumors among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiosensitizing agents, which help to make the treatment more potent owing to their numerous benefits, like improved tumor control, reduced toxicity, and synergistic effects with systemic therapies, is expected to drive the metastatic prostate cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metastatic prostate cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic prostate cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic prostate cancer market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the metastatic prostate cancer market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the metastatic prostate cancer market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current metastatic prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the metastatic prostate cancer market performed so far and how will it perform

in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the metastatic prostate cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the metastatic prostate cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of metastatic prostate cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of metastatic prostate cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of metastatic prostate cancer by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with metastatic prostate cancer across the seven major markets?

What is the size of the metastatic prostate cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of metastatic prostate cancer?

What will be the growth rate of patients across the seven major markets?

Metastatic Prostate Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for metastatic prostate cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the metastatic prostate cancer market?

What are the key regulatory events related to the metastatic prostate cancer market?

What is the structure of clinical trial landscape by status related to the metastatic prostate cancer market?

What is the structure of clinical trial landscape by phase related to the metastatic prostate cancer market?

What is the structure of clinical trial landscape by route of administration related to the metastatic prostate cancer market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 METASTATIC PROSTATE CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 METASTATIC PROSTATE CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 METASTATIC PROSTATE CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 METASTATIC PROSTATE CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 METASTATIC PROSTATE CANCER - UNMET NEEDS

10 METASTATIC PROSTATE CANCER - KEY ENDPOINTS OF TREATMENT

11 METASTATIC PROSTATE CANCER - MARKETED PRODUCTS

- 11.1 List of Metastatic Prostate Cancer Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Erleada (Apalutamide) - Janssen Research and Development
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Nubeqa (Darolutamide) - Bayer HealthCare/Orion

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

11.1.3 Pluvicto (Lutetium-177 vipivotide tetraxetan) - Advanced Accelerator

Applications

- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets

11.1.4 Lynparza (Olaparib) - AstraZeneca

- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

11.1.5 Rubraca (Rucaparib) - Clovis Oncology

- 11.1.5.1 Drug Overview
- 11.1.5.2 Mechanism of Action
- 11.1.5.3 Regulatory Status
- 11.1.5.4 Clinical Trial Results
- 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 METASTATIC PROSTATE CANCER - PIPELINE DRUGS

12.1 List of Metastatic Prostate Cancer Pipeline Drugs Across the Top 7 Markets

12.1.1 AZD 5305 - AstraZeneca

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 ORIC944 - ORIC Pharmaceuticals

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action

- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 RO 7656594 - Genentech
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 ARV110 - Arvinas
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. METASTATIC PROSTATE CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. METASTATIC PROSTATE CANCER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 METASTATIC PROSTATE CANCER - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Metastatic Prostate Cancer - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States

- 15.3.1 Metastatic Prostate Cancer - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Metastatic Prostate Cancer - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Metastatic Prostate Cancer - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Metastatic Prostate Cancer - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Metastatic Prostate Cancer - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Metastatic Prostate Cancer - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Metastatic Prostate Cancer - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Metastatic Prostate Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Metastatic Prostate Cancer - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Metastatic Prostate Cancer - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Metastatic Prostate Cancer - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Metastatic Prostate Cancer - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Metastatic Prostate Cancer - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Metastatic Prostate Cancer - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Metastatic Prostate Cancer - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Metastatic Prostate Cancer - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Metastatic Prostate Cancer - Access and Reimbursement Overview

16 METASTATIC PROSTATE CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 METASTATIC PROSTATE CANCER MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 METASTATIC PROSTATE CANCER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/MC2B60DD57D8EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC2B60DD57D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

